Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P-IL-2 + anti-PD-1 monoclonal antibody
- Development stage
- Unknown
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
P-IL-2 + anti-PD-1 monoclonal antibody refers to a combination or a bispecific molecule that targets both the interleukin 2 (IL‑2) pathway and the programmed cell death protein 1 (PD‑1) immune checkpoint. These agents are designed to enhance antitumor immunity by simultaneously blocking PD‑1-mediated T cell inhibition and providing IL‑2 signaling to stimulate T cells and natural killer (NK) cells. Some molecules in this category are engineered as bispecific antibodies or immunocytokines that bind PD‑1 on T cells while delivering IL‑2 activity preferentially to tumor-reactive lymphocytes. This dual mechanism aims to overcome limitations of high-dose IL‑2 therapy (toxicity) and resistance to checkpoint inhibitors by focusing immune activation within the tumor microenvironment[4][5][8]. Developers include various biotechnology companies working on next-generation immunotherapies for cancer.
- Other names
- PD1-IL2Ra-IL2PD-1-IL2Ra-IL2PD 1-IL2Ra-IL2PD1-IL2vPD-1-IL2vPD 1-IL2vanti-PD-1/IL-2 bispecific antibody fusion proteinalpha-PD1/IL2 fusion protein
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on P-IL-2 + anti-PD-1 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P-IL-2 + anti-PD-1 monoclonal antibody.